Randomized Trial in Interleukin-2 (IL-2) as Early Consolidation Following Marrow Ablation Therapy with Stem Cell Rescue for Metastatic Breast Cancer

2004 ◽  
Author(s):  
Wolfram E. Samlowski ◽  
Finn B. Peterson
Keyword(s):  
Breast Cancer ◽  
Stem Cell ◽  
Metastatic Breast Cancer ◽  
Randomized Trial ◽  
Interleukin 2 ◽  
Metastatic Breast ◽  
Ablation Therapy ◽  
Stem Cell Rescue ◽  
Marrow Ablation

Randomized Trial of High-Dose Chemotherapy With Autologous Peripheral-Blood Stem-Cell Support Compared With Standard-Dose Chemotherapy in Women With Metastatic Breast Cancer: NCIC MA.16

2008 ◽  
Vol 26 (1) ◽  
pp. 37-43 ◽  
Author(s):  
Michael Crump ◽  
Stefan Gluck ◽  
Dongsheng Tu ◽  
Doug Stewart ◽  
Mark Levine ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Stem Cell ◽  
Metastatic Breast Cancer ◽  
Randomized Trial ◽  
Induction Chemotherapy ◽  
Standard Dose ◽  
Metastatic Breast ◽  
Progression Free Survival ◽  
High Dose Chemotherapy ◽  
High Dose

Purpose We conducted a multicenter, randomized trial to compare progression-free survival (PFS), overall survival (OS), and quality of life in women with metastatic breast cancer (MBC) receiving high-dose chemotherapy plus autologous stem-cell transplantation (ASCT; HDCT) compared with standard-dose therapy. Patient and Methods Between April 1997 and December 2000, 386 women with MBC and no prior chemotherapy for metastatic disease were registered. After initial response to anthracycline- or taxane-based induction chemotherapy, 224 patients were randomly assigned: 112 to high-dose cyclophosphamide, mitoxantrone, and carboplatin chemotherapy and ASCT (HDCT), and 112 to standard therapy (ST). Median age was 47 years (range, 25 to 67 years). Thirty two percent of women randomly assigned had estrogen and progesterone receptor–negative breast cancer, 42% had visceral metastases, and 58% had bone metastases. Complete remission rates before random assignment were 11% for those receiving HDCT and 12% for those receiving ST. Results After a median follow-up of 48 months, 79 deaths were observed in the HDCT arm and 77 deaths were observed in the ST arm; seven patients (6%) in the HDCT arm died as a result of toxicity. The median OS was 24 months for the HDCT arm (95% CI, 21 to 35 months) and 28 months for ST (95% CI, 22 to 33 months; hazard ratio [HR], 0.9; 95% CI, 0.6 to 1.2; P = .43). PFS was 11 months for HDCT and 9 months for ST (HR, 0.6 in favor of HDCT; 95% CI, 0.5 to 0.9; P = .006). Conclusion HDCT did not improve OS in women with MBC when used as consolidation after response to induction chemotherapy.

Tandem and triple high-dose chemotherapy with autologous stem cell rescue in metastatic breast cancer

1998 ◽  
Vol 124 (12) ◽  
pp. 690-694 ◽  
Author(s):  
J. Huober ◽  
A. Schneeweiss ◽  
S. Hohaus ◽  
G. Wittmann ◽  
A. Meyer ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Stem Cell ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Stem Cell Rescue ◽  
Autologous Stem Cell Rescue
Sign in / Sign up

Export Citation Format

Share Document